• Twitter
• Facebook
• Snapchat
• Pinterest
• LinkedIn
• Tumblr

---

Fundamental analysis: Capricor Therapeutics, Inc. (CAPR)

Awarener score: 5.3

Conclusion

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

• Business has been growing at an extremely fast pace. It's been top tier when measured against peer companies.
• Capricor Therapeutics, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks bottom tier against rivals.

Margins score: 2.7

• CAPR profit margins -on goods and services sold- are usually extremely poor. They stand mediocre against rival companies.
• Business profit on sales tends to be pauper. It's last-in-rank when measured against competitors.
• Profits on sales made -available to repay debt and purchase properties- are usually huge. They remain impressive in relation to peers.
• Earnings -before income taxes and interests on loans taken- tend to be pauper in relation to total revenues. They're still somewhat worse than similar companies.
• Profits -before income taxes- are usually destitute considering total sales, and remain below average when measured against rivals.
• Total net profit tends to be pauper when confronted to sales. Company stands below average when measured against comparable firms.

Growth score: 1.1

• Capricor Therapeutics, Inc. profit -on goods and services sold- has been shrinking. It's been in a very weak position compared to competitors.
• In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
• In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
• In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
• In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
• In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
• The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 4.3

• CAPR had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
• Research and development expenses consume a very large portion of revenues. It's below average when measured against competitors.
• The company shows excellent business growth in relation to research and development efforts. It stands impressive in relation to rival companies.

Profitability score: 1.2

• Capricor Therapeutics, Inc. usually gets pauper returns on the resources it controls. It proves below average when measured against peer firms.
• The company normally gets extremely poor proceeds -on the resources directly invested in the business-. They remain in a very weak position compared to similar companies.
• There's usually bottom profitability -in relation to owned resources-. It ranks weak when measured against competitors.
• In the past, got very poor returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's below average when measured against comparable enterprises.

Usage of Funds score: 2.8

• CAPR on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands below average when measured against rival firms.
• The company is usually largely investing in new property, plant, and equipment, to expand its operating capabilities, which is more than average in relation to industry peers.
• In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
• The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
• As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
• The company has greatly enlarged the pool of investors in previous years, resulting in more mouths feeding on the pie of profits. It remains in a very weak position compared to peer enterprises.
• Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
• We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 5.2

• Capricor Therapeutics, Inc. has no intangible assets (like brands and goodwill) according to accounting books, which is safest. It happens to be top tier when measured against peer companies.
• The company has roughly double short-term resources than short-term obligations. Liquidity concerns are normally not an issue. It turns to be in a very weak position compared to similar firms.
• A very minor portion of resources controlled were provided for with financial debt. Financial strength is solid. Company could increase debt if it wished so, to reinvest in business, to buy a smaller company or to reward stockholders. It remains slightly worse than rival firms.
• A substantial portion of resources controlled are already cash or short-term investments, which is better for liquidity. It looks similar to rivals.
• For every dollar of short-term obligations, the company has more than enough dollars in cash and short-term receivables. It's in a very weak position compared to peer firms.
• For every dollar of short-term obligations, the company has enough dollars in cash and equivalents, which is worse than most similar enterprises.
• Usually, sales are on somewhat more than three months credit. It still ranks substantially worse when measured against peers.
• Days of inventory outstanding are not known. It comes up as a big question mark against competitors.
• We could not gauge the normal operating cycle of the company. It happens to be a mystery against peers.
• Unfortunately, we had not enough data to estimate the days of payables outstanding. It ranks unknown against industry peers.
• Cash conversion cycle remains unknown, due to not having enough inputs. It's incomparable against similar companies.
• To what extent normalized EBITDA covers interest expenses is not known. It stands impossible to compare against rival firms.
• Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
• Last twelve months revenues were non-significant in relation to fixed assets. The company must improve income to take advantage of used resources. It looks rather normal in relation to similar firms.
• Resources exploitation is virtually zero, as the firm hardly reports any sales. It's still somewhat better than peer companies.

Valuation score: 3.5

• Capricor Therapeutics, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
• Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains in a very weak position compared to peers.
• In the past twelve months, the company neither generated nor consumed funds. Whatever funds it could get, it reinvested in the business, which stands better than most similar companies.
• The company usually consumes more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving business growth, genuine profitability may be brought into question. It's still encouraging in relation to industry firms.
• In the past twelve months, the company has significantly rewarded investors, considering both dividends and share on the pie of earnings. It came up impressive in relation to peer ventures.
• This company is a cash hoarder. It might be well poised to substantially increase stockholder payments, or to fund new business projects. It looks slightly better than similar enterprises.
• Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
• Comparing the current stock price with the past twelve-months revenues gives a huge relationship. The stock price might rely more on expectations and resources controlled than on anything else. It looks in a weak position compared to rival firms.
• The relation between the stock price and accounting book value is extremely high, which may be good or bad depending on context. Run again in analytic mode if you want to dig deeper. The company remains worse than most peer firms.
• In the past twelve months, the operating business lost a lot of money. It happens to be encouraging in relation to industry peers.
• In an alternate metric of bang for the buck, the company has usually shown a very low earnings power ability when measured against the current stock price and financial position. Profitability is in dispute. It's still a slight improvement compared to peer companies.

Total score: 3.3

---

Awarener score: 5.3

Conclusion

Support us!

We are an independent project. No ads, no suscription, no registration required.

• Donate!